Literature DB >> 28575437

Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy.

Ivan Gentile1, Antonio Riccardo Buonomo1, Alberto Enrico Maraolo1, Riccardo Scotto1, Federico De Zottis1, Gianfranco Di Renzo2, Guglielmo Borgia1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28575437     DOI： 10.1093/jac/dkx172

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  4 in total

1.  Ceftolozane/tazobactam for the treatment of MDR Pseudomonas aeruginosa left ventricular assist device infection as a bridge to heart transplant.

Authors:  Maddalena Peghin; Massimo Maiani; Nadia Castaldo; Filippo Givone; Elda Righi; Andrea Lechiancole; Assunta Sartor; Federico Pea; Ugolino Livi; Matteo Bassetti
Journal:  Infection       Date:  2017-10-31       Impact factor: 3.553

2.  Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR Pseudomonas aeruginosa in patients with impaired renal function: a case series from a single-center experience.

Authors:  A R Buonomo; A E Maraolo; R Scotto; M Foggia; E Zappulo; P Congera; S Parente; I Gentile
Journal:  Infection       Date:  2020-01-24       Impact factor: 3.553

Review 3.  Multidrug-Resistant Pseudomonas Infections: Hard to Treat, But Hope on the Horizon?

Authors:  Lynn Nguyen; Joshua Garcia; Katherine Gruenberg; Conan MacDougall
Journal:  Curr Infect Dis Rep       Date:  2018-06-06       Impact factor: 3.725

4.  Real-world use of ceftolozane/tazobactam: a systematic literature review.

Authors:  Laura Puzniak; Ryan Dillon; Thomas Palmer; Hannah Collings; Ashley Enstone
Journal:  Antimicrob Resist Infect Control       Date:  2021-04-08       Impact factor: 4.887
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.